Edwards Lifesciences Corporation (EW) Intrinsic Value & DCF Valuation

Medical - Devices · NYSE

Current Price

$101.85

Intrinsic Value

$94.43

-7.9% margin of safety

What Is Edwards Lifesciences Corporation's Intrinsic Value?

As of 2026-11-20, the base-case DCF model estimates the intrinsic value of Edwards Lifesciences Corporation (EW) at $94.43 per share, compared with a market price of $101.85, a margin of safety of -7.9%. The base case assumes 12.0% annual free cash flow growth and a 10.0% discount rate.

Across the sensitivity grid the estimate spans $79.3 to $111.58. Intrinsic value is an estimate built on assumptions, not a fact. A higher discount rate or slower growth pushes the estimate down, while stronger cash flow growth lifts it.

How the DCF works · Recalculate with your own assumptions · What is intrinsic value?

Is Edwards Lifesciences Corporation (EW) Undervalued?

At $101.85, EW trades about 7.9% above the base-case intrinsic value estimate, a modest premium. By this model the price sits within a normal band, though faster growth than assumed would change the picture.

Assessment by Charlie Wang, a former auditor

AI MOAT & RISK ANALYSIS
AI Generated · For Reference OnlyEW

COMPETITIVE MOAT

↑Strong TAVR Market Leadership

Edwards Lifesciences holds a dominant position in the Transcatheter Aortic Valve Replacement (TAVR) market. This leadership is built on extensive clinical data and physician adoption.

↑Proprietary Technology and Innovation

The company invests heavily in R&D, leading to patented technologies and a pipeline of innovative devices. This drives product differentiation and customer loyalty.

↑Established Physician Relationships

Long-standing relationships with cardiologists and cardiac surgeons create high switching costs. Physicians are trained on and trust Edwards' systems.

INVESTMENT RISKS

↓Intensifying Competition in TAVR

While Edwards leads TAVR, competitors are developing advanced technologies. This could lead to price pressures and market share erosion over time.

↓Macroeconomic and Currency Headwinds

Global economic conditions and currency fluctuations can impact international sales and profitability. Tariffs also pose a threat to cost structures.

↓Reimbursement and Payer Policies

Changes in healthcare reimbursement policies or payer decisions could affect the adoption and affordability of Edwards' high-value devices.

Base case

EW base case valuation

Intrinsic Value

$94.43

Margin of safety

-7.9%

Expected annual return

-1.5%

Base case assumptions: 12.0% annual growth, 10.0% discount rate, 30x exit multiple, 5 year projection. Data as of 2026-11-20.

This base case uses default assumptions and is not financial advice. The intrinsic value changes significantly when the growth rate or discount rate changes. Open the calculator to set your own assumptions and see the full sensitivity range.

Customize the EW valuation

Adjust the growth rate, discount rate, and exit multiple to see how the intrinsic value and margin of safety for Edwards Lifesciences Corporation respond.

Open DCF Calculator for EW

Or try PE Ratio Valuation for EW →

Company Overview

Edwards Lifesciences Corporation is a global medical technology firm specializing in sophisticated products and technologies for structural heart conditions, alongside critical care and surgical patient monitoring. With operations spanning the United States, Europe, Japan, and various international territories, the company offers a comprehensive suite of solutions. Their structural heart disease portfolio encompasses transcatheter heart valve replacement systems designed for minimally invasive procedures, as well as transcatheter repair and replacement options specifically targeting mitral and tricuspid valve pathologies, exemplified by their PASCAL and Cardioband systems. Additionally, they provide advanced surgical structural heart solutions, including the INSPIRIS aortic surgical valve, the KONECT RESILIA pre-assembled aortic tissue valved conduit for complex valve, root, and ascending aorta replacements, and the HARPOON Beating Heart Mitral Valve Repair System for patients suffering from degenerative mitral regurgitation. In the realm of critical care, Edwards supplies advanced hemodynamic monitoring systems that assess patients' cardiac function and fluid status in both surgical and intensive care environments. This offering also features the Acumen Hypotension Prediction Index software, which provides early alerts to clinicians regarding potential dangerously low blood pressure. The company distributes its products to healthcare providers through a combination of its proprietary sales force and independent distributor networks. Founded in 1958, Edwards Lifesciences Corporation maintains its headquarters in Irvine, California.

Financial Metrics — EW Stock Valuation Data

Revenue/Share (TTM)

$11.58

FCF/Share (TTM)

$2.47

ROIC (TTM)

9.1%

ROE (TTM)

9.7%

P/FCF

41.1x

EV/EBITDA

35.0x

FCF Yield

2.43%

Debt/Equity

0.06x

Based on trailing twelve-month data, EW shows a free cash flow per share of $2.47 and a ROIC of 9.1%, key inputs for stock valuation using the DCF method. The P/FCF ratio of 41.1x and FCF yield of 2.43% are important context metrics when evaluating EW's stock valuation relative to peers.

Frequently Asked Questions

What is the intrinsic value of EW?

Edwards Lifesciences Corporation currently generates $2.47 in free cash flow per share. At the current price of $101.85, a DCF model would discount these cash flows at an appropriate WACC and apply a terminal growth rate to arrive at an intrinsic value. The result depends heavily on your growth and discount rate assumptions — a 1% change in WACC typically shifts the fair value estimate by 10-15%. In MiniValuator the model uses a single discount rate that you can edit directly, 10% by default, rather than a computed WACC.

Is EW undervalued?

EW trades at a P/FCF ratio of 41.1x with a free cash flow yield of 2.43%. A high P/FCF means investors are paying more per dollar of free cash flow, which usually reflects expectations of future growth. However, whether EW is truly undervalued requires comparing the DCF intrinsic value to the current market price and evaluating whether the margin of safety is sufficient for your risk tolerance.

How do I value EW stock using DCF?

To perform a DCF valuation on Edwards Lifesciences Corporation: (1) Start with the trailing free cash flow per share ($2.47) as the base, (2) project future FCF growth over 5-10 years based on Medical - Devices industry trends and company fundamentals, (3) apply a discount rate (WACC) reflecting EW's risk profile — with a debt-to-equity of 0.06x, capital structure is an important factor, and (4) add a terminal value for cash flows beyond the projection period.

What is DCF valuation and how does it apply to EW?

DCF (Discounted Cash Flow) estimates what a company is worth today based on its future cash generation. For Edwards Lifesciences Corporation, this means projecting how much free cash flow the company will produce over the next 5-10 years, shaped by Medical - Devices trends, then discounting those amounts to today's dollars. EW's ROIC of 9.1% shows moderate capital returns.

How does WACC affect EW stock valuation?

WACC (Weighted Average Cost of Capital) is the discount rate in a DCF model — it reflects the minimum return investors require. For EW, with a debt-to-equity ratio of 0.06x, the capital structure directly influences WACC. A 1% increase in WACC typically reduces the intrinsic value by 10-15%. At an EV/EBITDA of 35.0x, the market's implied discount rate can be reverse-engineered for comparison. In MiniValuator you set this discount rate yourself as a single editable number, 10% by default, instead of computing a formal WACC.

Learn More

Related Valuations

All Healthcare valuations

DCF and P/E value EW with different methods and assumptions, so the two conclusions can differ. Compare the P/E fair value.

Price as of 2026-11-20. Financial data from Financial Modeling Prep (trailing twelve months) · Valuation methodology by Charlie Wang.

This is an estimate, not investment advice.